Packard A B, Srivastava S C, Richards P, Meinken G E, Ford L, Benson W R
Division of Nuclear Medicine, Children's Hospital, Harvard Medical School, Boston, Mass 02115.
Int J Rad Appl Instrum B. 1989;16(3):291-4. doi: 10.1016/0883-2897(89)90010-x.
In the development of technetium-99m radiopharmaceuticals for the evaluation of regional cerebral perfusion, one series of complexes that has remained unexplored is the neutral lipophilic tris complexes formed with beta-diketonato ligands. The prototype complex of this series, tris(2,4-pentanedionato) technetium(III), has been prepared via a new synthetic route and chemically characterized using 99Tc and the biodistribution of the no-carrier-added 99mTc complex has been determined. The 99mTc complex was found to be distributed throughout the body with persistent high blood levels indicative of a high degree of protein binding. The primary route of excretion was the hepatobiliary system as indicated by the appearance of 99mTc in the gut and feces at longer sample times post-injection. Although this complex was not retained by the brain, it does provide a starting point from which a more effective agent might be developed.
